Biotricity Launches Biocare Cardiac Application for Samsung’s Galaxy Watch4 Series
REDWOOD CITY, CA / ACCESSWIRE / October 7, 2021 / Biotricity Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology...
News
Ground-Breaking Clinical Data from INSIGHT Trial Presented at VIVA
Study Outcomes Demonstrate Safety and Efficacy of Pantheris for Treatment of In-Stent RestenosisREDWOOD CITY, CA / ACCESSWIRE / October 7,...
Canadian Study Using Cloud DX Technology Proves Remote Patient Monitoring Improves Patient Outcomes
Research using Canadian technology by Cloud DX provides evidence healthcare decision-makers need; RPM improves patient outcomes and healthcare delivery.News in...
Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relating to a potent and highly selective investigational RET inhibitor
Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relating to a potent and highly selective investigational RET inhibitor Lugano,...
Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Tumor shrinkage and partial responses observed in patients with advanced head and neck squamous cell carcinoma (HNSCC) treated with MCLA-158In...
Sienna Maintains DBRS Ratings of “BBB” with Stable Trends
MARKHAM, Ontario, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) announced the...
Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment
Meeting, taking place October 7-10, 2021, is hosted by the American Association for Cancer Research (AACR), the National Cancer Institute...
Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
– Lead oral PRMT5 inhibitors PRT543 and PRT811 demonstrate favorable safety profile, evidence of preliminary clinical activity including durable responses...
Privia Health to Report Third Quarter 2021 Results on Monday, November 8
ARLINGTON, Va., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it plans to...
Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Granted Rare Pediatric Disease Designation by FDA
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB), a commercial-stage biopharmaceutical...
Kinnate Biopharma Inc. Details Two-Part Phase 1 Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference
First in human, multicenter, non-randomized, open-label trial has expanded to three sites and is actively recruitingSAN FRANCISCO and SAN DIEGO,...
Skye Bioscience Appoints Head of Regulatory Affairs & Quality Assurance and Senior Director of Research & Development
SAN DIEGO, CA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary...
Monte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degraders for the Treatment of Myc-driven Cancer
Data Demonstrate Novel Link Between GSPT1 and Myc-induced Transcription and Protein TranslationBOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Monte Rosa...
Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
AMX-818, an HER2-targeted T cell engager (TCE), is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated TCE) platform designed to...
Rakovina Therapeutics Inc. Receives Notice of Allowance for New U.S. Patent Covering kt-2000 series PARP Inhibitors
VANCOUVER, British Columbia, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSX-V: RKV) today announced that the...
Allied Corp Announces Signing of Supply Contracts of 85,000, 40,000 and 24,000 Kilograms for the 2022 Calendar Year
KELOWNA, British Columbia, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to...
ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC
ORIC-101 and enzalutamide combination regimen at the recommended Phase 2 dose was well tolerated; adverse events generally consistent with single...
Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα
RLY-2608 preferentially binds mutant PI3Kα at a novel allosteric site discovered by the Dynamo™ platform Preclinically, achieved tumor regressions in vivo...
Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that...
Yield10 Bioscience to Participate in Maxim Group AgTech Virtual Conference
WOBURN, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, announced today that President...